自身抗体谱与硬皮病肾危象的发病及死亡相关
本研究回顾性分析京都大学医院330例系统性硬化症患者,SRC见于24例(7%)。抗U1-RNP、抗拓扑异构酶I和抗RNA聚合酶III与SRC发生相关,抗拓扑异构酶I与SRC后1年死亡相关。SRC后1年总生存率54%,抗拓扑异构酶I阳性者33%,阴性者75%。
要点
- 抗U1-RNP、抗拓扑异构酶I、抗RNAPIII与SRC发生相关(OR分别为3.63、3.22、3.29)。
- 抗拓扑异构酶I与SRC后1年死亡相关(OR 6.00)。
- SRC后1年生存率:抗拓扑异构酶I阳性33% vs 阴性75%。
核心结论
- 特定SSc相关自身抗体与SRC的发病和死亡相关。
研究设计与样本
- 回顾性分析京都大学医院330例系统性硬化症(SSc)患者的临床特征和死亡情况,重点分析抗拓扑异构酶I(anti-topo I)、抗着丝点(ACA)、抗RNA聚合酶III(RNAPIII)和/或抗U1-RNP与SRC的关联,采用逻辑回归分析。
主要发现
- 330例SSc患者中24例发生SRC,其中抗拓扑异构酶I阳性12/24(50%)、抗RNAPIII阳性7/24(29%)、抗U1-RNP阳性5/24(21%)、ACA阳性3/24(13%)。
- 抗U1-RNP [OR 3.63(95%CI 1.11, 10.2)]、抗拓扑异构酶I [OR 3.22(95%CI 1.37, 7.57)]和抗RNAPIII [OR 3.29(95%CI 1.16, 8.70)]与SRC发生相关。
- 抗拓扑异构酶I [OR 6.00(95%CI 1.11, 41.1)]与SRC后1年死亡相关。
- SRC起病后1年生存率:全部患者54%,抗拓扑异构酶I阳性者33%,抗拓扑异构酶I阴性者75%。
- 抗拓扑异构酶I阴性者中,抗RNAPIII阳性者1年生存率83%,ACA阳性者100%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to investigate association of autoantibodies with scleroderma renal crisis (SRC) among Japanese patients. METHODS: The clinical characteristics and mortality of 330 patients with sytemic screlosis (SSc) at Kyoto University Hospital were retrospectively analysed, focusing on possible association with anti-topoisomerase I (anti-topo I), anti-centromere (ACA), anti-RNA polymerase III (RNAPIII) and/or anti-U1-RNP. Logistic regression analyses were performed to reveal any association of these autoantibodies with the development and mortality of SRC. RESULTS: SRC was observed in 24 out of 330 SSc patients, including patients with anti-topo I (n = 12/24, 50%), anti-RNAPIII (n = 7/24, 29%), anti-U1-RNP (n = 5/24, 21%) and ACA (n = 3/24, 13%). Anti-U1-RNP [odds ratio (95% CI), 3.63 (1.11, 10.2)], anti-topo I [3.22 (1.37, 7.57)] and anti-RNAPIII (3.29 [1.16, 8.70]) were associated with the development of SRC. Furthermore, anti-topo I [6.00 (1.11, 41.1)] was associated with 1-year mortality of SRC. The 1-year survival rate after the onset of SRC among all patients and among those positive for anti-topo I was 54% and 33%, respectively. In contrast, the survival rate in patients negative for anti-topo I was 75%, of which the survival rate of patients positive for anti-RNAPIII and ACA was 83% and 100%, respectively. CONCLUSION: Specific SSc-related autoantibodies were associated with the morbidity and mortality of SRC.
引用
- Tsuji H, Kuramoto N, Sasai T, et al. Autoantibody profiles associated with morbidity and mortality in scleroderma renal crisis. Rheumatology (Oxford). 2022. PMID: 35078211. doi:10.1093/rheumatology/keac047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。